Answers are grounded in this paper and cite their sources.
Randomized trial compares long-term bowel function and quality of life in rectal cancer treatments, suggesting benefits of organ-preserving strategies.
Background: Bowel dysfunction and quality of life (QoL) are key determinants of long-term outcomes after treatment for localized rectal cancer (cT2–cT3a–b, N0, M0). Total mesorectal excision (TME) provides effective oncologic control but may cause substantial functional impairment. Organ-preserving strategies combining chemoradiotherapy with local excision may improve functional outcomes, yet long-term patient-reported data remain limited. Materials and Methods: TAUTEM is a multicenter, prospective, open-label, phase 3, randomized, noninferiority trial comparing chemoradiotherapy followed by transanal endoscopic microsurgery (CRT–TEM) with standard TME in patients with T2–T3ab, N0, M0 rectal cancer. Long-term bowel function was assessed using the Low Anterior Resection Syndrome (LARS) score ≥24 months after definitive treatment. Quality of life (QoL) was evaluated using the EORTC QLQ-C30, QLQ-CR38, and the Karnofsky Performance Status at baseline and after treatment. Analyses were conducted in the modified intention-to-treat and per-protocol populations. Results: Of 173 randomized patients, 162 were included in the modified intention-to-treat analysis (81 per group). Long-term LARS assessment was available for 96 of 102 eligible patients (94%) at a median follow-up of 87.5 months. Global QoL was higher after CRT–TEM than after TME (median 83.3 vs 66.7; P = 0.02). Permanent stoma rates were lower following CRT–TEM than after TME (7.4% vs 28.4%). Major LARS occurred less frequently after CRT–TEM than after TME (7.7% vs 36.4%; P = 0.001), with higher rates of no LARS (80.8% vs 47.7%; P = 0.001). Item-level outcomes (frequency, urgency, clustering, and flatus incontinence) consistently favored CRT–TEM. Conclusions: CRT–TEM was associated with substantially less long-term bowel dysfunction and superior QoL compared with TME, together with markedly fewer permanent stomas. These findings support organ-preserving strategies for selected patients with cT2–cT3a–b, N0, M0 rectal cancer.
No takes yet. Share an insight, caveat, or question.
Serra‐Aracil et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: